Cargando…
LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature
BACKGROUND: For managing nonmotor symptoms (NMS) in advanced Parkinson's disease (PD), levodopa–carbidopa intestinal gel (LCIG) infusion is of interest as it shows lesser plasma fluctuations of both drugs as compared to oral levodopa–carbidopa (LC). OBJECTIVES: To highlight LCIG effect in NMS a...
Autores principales: | Kamel, Walaa A., Al‐Hashel, Jasem Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507541/ https://www.ncbi.nlm.nih.gov/pubmed/32677345 http://dx.doi.org/10.1002/brb3.1757 |
Ejemplares similares
-
Unexplained worsening of parkinsonian symptoms in a patient with advanced Parkinson’s disease as the sole initial presentation of COVID-19 infection: a case report
por: Kamel, Walaa A., et al.
Publicado: (2021) -
Parkinsonism as a Complication of Bariatric Surgery
por: Kamel, Walaa A., et al.
Publicado: (2015) -
Reply to Letter to Editor: Is SARS-CoV-2 responsible for relapses of Parkinson’s disease?
por: Kamel, Walaa A., et al.
Publicado: (2021) -
Guillain-Barre Syndrome following COVID-19 Infection: First Case Report from Kuwait and Review of the Literature
por: Kamel, Walaa A., et al.
Publicado: (2021) -
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
por: Bergquist, Filip, et al.
Publicado: (2022)